Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Novel allogeneic BCMA CAR-expressing iNKT cells with PD1 deletion demonstrate superior tumor control in a multiple myeloma preclinical model

View Full Paper
Ask AI
Bookmark
Share

Authors

SYShulin YangGuangxi UniversityBZBiao ZhouChina-Japan Friendship HospitalYCYuzhu CuiInner Mongolia Agricultural University

Discussion

Loading...

Member takes

Overview

Novel iNKT cell therapy enhances tumor control in multiple myeloma, indicating superior efficacy and reduced disease burden.

Key Points

  • This research aims to evaluate the efficacy of a novel allogeneic CAR-iNKT cell therapy targeting multiple myeloma.
  • Developed a PD1-deleted iNKT cell therapy targeting BCMA.
  • Used H929-luc cells in a xenograft model in NOG-hIL15Tg mice.
  • Monitored tumor control through bioluminescence after CAR-iNKT cell injections.
  • The CAR-iNKT with PD1 deletion showed improved long-term cytotoxicity against H929 cells.
  • Tumor control was significantly better in the PD1-deleted CAR-iNKT model in vivo by day 35.
  • The findings suggest potential advantages of allogeneic cell therapy in R/R multiple myeloma.

Cite This Study

Yang et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d193https://doi.org/10.1182/blood-2025-5847
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Enhancing iNKT cell immunotherapy through the integration of optimized CAR endodomains and iNKT engagers2026
  2. 2Abstract 1322: A cryopreserved allogeneic anti-BCMA CAR-NK cellular therapy exhibits both innate and CAR-mediated MM cell killing <i>in vitro</i> and <i>in vivo</i>2024 · 1 citations
  3. 3Abstract 3618: High-avidity BCMA CAR and high-affinity, non-cleavable CD16 Fc receptor incorporated in off-the-shelf CAR T cells promote multi-antigen targeting and durable anti-tumor cytotoxicity in the treatment of multiple myeloma2024 · 1 citations
  4. 4Abstract 137: Harnessing allogeneic CAR-iNKT cells for next-generation treatments in oncology and autoimmunity.2026
  5. 5BCMA-CAR Natural Killer Cells Suppress Myeloma in Bone Marrow but Allow Emergence of Extramedullary Disease 22666802026